Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Pharma News | BioPharma Dive
Nov 14, 2024 · The latest pharma news for biotech and biopharmaceutical professionals
Iovance, with approval of ‘TIL’ cell therapy, readies for complex ...
Feb 20, 2024 · Dive Insight: Amtagvi’s approval has been a long time coming for Iovance. TIL therapy originated from research at the National Institutes of Health in the 1980s.It took decades to fine-tune, and Iovance had to overcome multiple regulatory delays bringing the therapy, formerly known as lifileucel, to market.. Its clearance is the “culmination of scientific and …
Biotech News - BioPharma Dive
Nov 15, 2024 · ‘Find any advantage’: 3 biotech leaders on driving R&D success “Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel hosted by BioPharma Dive.
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
Novartis wins FDA approval for new heart drug, but faces uphill …
Dec 22, 2021 · Novartis on Wednesday won Food and Drug Administration approval for a genetic drug that can powerfully lower cholesterol with just two injections a year, one that it hopes could be widely used to lower the risk of heart disease complications.. Called Leqvio, the drug works similarly to approved cholesterol-cutting medicines from Amgen and partners Sanofi and …
Two decades and $200 billion: AbbVie’s Humira monopoly nears …
Mar 17, 2022 · All told, AbbVie filed about 250 patent applications for Humira in the U.S., 90% of them following the drug's 2002 approval, according to the advocacy group Initiative for Medicines, Access & Knowledge. One hundred and thirty have been granted. The strengthened patent shield has stretched AbbVie's legal monopoly in the U.S. for six years beyond the expiration of …
Clinical Trial News - BioPharma Dive
5 days ago · The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs compare. As novel therapeutics become more complex — and costly — to bring to market, drug ...
A decade of cancer immunotherapy: Keytruda, Opdivo and the …
Sep 4, 2024 · Developed by Bristol Myers Squibb, Opdivo was the second so-called PD1 inhibitor to be approved in the U.S. The first, Merck & Co.’s Keytruda, won Food and Drug Administration clearance 10 years ago today. Keytruda’s initial U.S. approval, which preceded Opdivo’s by a few months, was niche, reserved for people with inoperable melanoma or whose disease had …
Biohaven starts life as new company following Pfizer buyout
Oct 5, 2022 · Leading its drug research and development are Chief Medical Officer Irfan Qureshi, who was previously an executive at the old Biohaven; Chief Development Officer Tanya Fischer, previously at Alnylam Pharmaceuticals; and Chief Scientific Officer Bruce Car, who most recently was the top scientist at Agios Pharmaceuticals.